[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360790-105":59,"doc-detail-360790-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","perioperative-toripalimab-plus-chemotherapy-versus-chemotherapy-alone-in-locally-advanced-gastric-or-gastroesophageal-junction-cancer-3-year-follow-up-of-neosummit-01-trial","Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer - 3-Year Follow-Up of NEOSUMMIT-01 Trial","","The NEOSUMMIT-01 trial previously found that perioperative toripalimab added to chemotherapy improved pathologic response in locally advanced gastric or gastroesophageal junction cancer. Extended follow-up reports event-free survival (EFS) and overall survival (OS) outcomes. Among 108 enrolled patients, 3-year EFS reached 74.7% versus 56.2% (HR 0.51, P=.044) and 3-year OS was 81.3% versus 72.2% (HR 0.45, P=.036). Benefits were consistent across most subgroups and persisted after excluding dMMR.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/perioperative-toripalimab-plus-chemotherapy-versus-chemotherapy-alone-in-locally-advanced-gastric-or-gastroesophageal-junction-cancer-3-year-follow-up-of-neosummit-01-trial/360790/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/perioperative-toripalimab-plus-chemotherapy-versus-chemotherapy-alone-in-locally-advanced-gastric-or-gastroesophageal-junction-cancer-3-year-follow-up-of-neosummit-01-trial/360790.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment strategy was evaluated in the NEOSUMMIT-01 trial follow-up?","Question",{"text":113,"@type":114},"The trial compared perioperative toripalimab plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric or gastroesophageal junction cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients were enrolled, and what were the group sizes?",{"text":118,"@type":114},"A total of 108 patients were enrolled, with 54 receiving toripalimab plus chemotherapy and 54 receiving chemotherapy alone.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key 3-year efficacy outcomes?",{"text":122,"@type":114},"At the cutoff, 3-year EFS was 74.7% vs 56.2% (HR 0.51, P=.044) and 3-year OS was 81.3% vs 72.2% (HR 0.45, P=.036), favoring toripalimab plus chemotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360790,1790522282,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Clinical Trial Updates  \nPerioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial  \nRun-Cong Nie, MD, PhD1 ; Ying Jin, MD, PhD2,3  ; Cheng-Cai Liang, MD, PhD1; Yuan-Fang Li, MD, PhD1  ; Ying-Bo Chen, MD1; Xiao-Wei Sun, MD1; Wen-Long Guan, MD, PhD2,3; Zi-Xian Wang, MD, PhD2,3  ; Hai-Bo Qiu, MD, PhD1 ; Wei Wang, MD, PhD1; Shi Chen, MD, PhD4;  \nDong-Sheng Zhang, MD, PhD2,3; Yi-Hong Ling, MD, PhD5; Shao-Yan Xi, MD, PhD5; Mu-Yan Cai, MD, PhD5  ; Jun Chi, MD6; Qiu-Xia Yang, MD7; Zhi-Min Liu, MD, PhD1; Yuan-Xiang Guan, MD1; Yong-Ming Chen, MD, PhD1; Ji-Bin Li, MD, PhD8  ; Xiong-Wen Tang, MD, PhD9,10 ;  \nJun-Sheng Peng, MD, PhD4; Feng Wang, MD, PhD2,3  ; Zhi-Wei Zhou, MD, PhD1; Rui-Hua Xu, MD, PhD2,3  ; and Shu-Qiang Yuan, MD, PhD1   \nDOI [https://doi.org/10.1200/JCO-25-02842](https://doi.org/10.1200/JCO-25-02842)  \nABSTRACT  \nThe NEOSUMMIT-01 trial previously showed that adding the PD-1 antibody toripalimab to perioperative chemotherapy improved the pathologic response in patients with locally advanced gastric or gastroesophageal junction cancer. Here, we present the event-free survival (EFS) and overall survival (OS) after extended follow-up. A total of 108 patients were enrolled (toripalimab plus chemotherapy, n 5 54; chemotherapy alone, n 5 54) . Atthe data cutoff date (August 29, 2025), the median follow-up was 43.2 months (interquartile range: 36.6-53.7). The 3-year EFS was 74.7%(95% CI, 63.6% to 87.7%) in the toripalimab plus chemotherapy group and 56.2%(95% CI, 43.3% to 73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.51 (95% CI, 0.27 to 0.98; P 5 .044) . The 3-year OS was 81.3%(95% CI, 71.4% to 92.4%) versus 72.2%(95% CI, 61.2% to 85.2%), respectively, with an HR of 0.45 (95% CI, 0.21 to 0.95; P 5 .036) . The survival beneﬁts were consistent across most predeﬁned subgroups and were maintained in the analysis excluding patients with dMMR. In conclusion, perioperative toripalimab plus chemotherapy signiﬁcantly improved 3-year EFS and OS compared with chemotherapy alone, suggesting it as a promising treatment option for patients with locally advanced gastric or gastroesophageal junction cancer.  \nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \n Protocol  \nAccepted March 25, 2026 Published May 5, 2026  \nJ Clin Oncol 44:1869-1875 © 2026 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nMultimodal perioperative therapy is recommended as the standard of care for localized gastric or gastroesophageal junction adenocarcinoma.1-4 Adjuvant chemotherapy after D2 gastrectomy represents the standard in Asia,5,6 whereas in Western counties, a perioperative triplet regimen with curative resection is recommended for this localized disease.7,8 The FLOT4 trial established the perioperative ﬂuorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) asthe standard of care in many counties outside of Asia.8 Evidence from several randomized trials in Asia also supports the use of perioperative chemotherapy.9,10 The RESOLVE trial showed that perioperative SOX (S-1 and oxaliplatin) provided superior overall survival (OS) and disease-free survival (DFS) compared with adjuvant capecitabine and oxaliplatin (CapOx) in the Chinese population.4,9 Despite these results, relapse and metastasis continue to pose a major challenge  \nfor a substantial proportion of patients even after perioperative chemotherapy.  \nThe combination of anti–PD-1 and PD-L1 therapy with chemotherapy has emerged as a new standard of care, demonstrating signiﬁcant survival beneﬁts in the ﬁrst-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma.11-15 A few randomized trials have reported promising efﬁcacy for anti–PD-1 and PD-L1 therapy combined with chemotherapy in the perioperative setting for localized gastric ca","cbCaiblNLswdCjIU","https://ap.wps.com/l/cbCaiblNLswdCjIU","pdf",871528,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What treatment strategy was evaluated in the NEOSUMMIT-01 trial follow-up?\",\"answer\":\"The trial compared perioperative toripalimab plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric or gastroesophageal junction cancer.\"},{\"question\":\"How many patients were enrolled, and what were the group sizes?\",\"answer\":\"A total of 108 patients were enrolled, with 54 receiving toripalimab plus chemotherapy and 54 receiving chemotherapy alone.\"},{\"question\":\"What were the key 3-year efficacy outcomes?\",\"answer\":\"At the cutoff, 3-year EFS was 74.7% vs 56.2% (HR 0.51, P=.044) and 3-year OS was 81.3% vs 72.2% (HR 0.45, P=.036), favoring toripalimab plus chemotherapy.\"}]","Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer - 3-Year Follow-Up of NEOSUMMIT-01 Trial | PDF",1790141573,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7026b89db716d66a6a3a712043b2358b.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6418c018d1e171e02b1d6c94e1fe84ef.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ba613deb5f477bbfd5c72c2c8da098e.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39eecf273255b8261039a6ea935dd734.webp",980,1311]